Cochrane Db Syst Rev
-
Cochrane Db Syst Rev · Oct 2013
Review Meta AnalysisNarrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis.
The most commonly used types of phototherapy for treating psoriasis are narrow-band ultraviolet B (NB-UVB); broad-band ultraviolet B (BB-UVB), which includes selective (delivering radiation with a wavelength range of 305 to 325 nm) and conventional BB-UVB (280 to 320 nm); and psoralen ultraviolet A photochemotherapy (oral or bath PUVA). There is substantial controversy regarding their efficacy when compared with each other. ⋯ Current evidence is very heterogeneous and needs to be interpreted with caution. The clearance rate between oral PUVA and NB-UVB is inconsistent among the included studies. Evidence regarding NB-UVB versus bath PUVA is also inconsistent. Re-NB-UVB and re-PUVA are similarly effective for treating people with CPP or GP. In practice, NB-UVB may be more convenient to use since exogenous photosensitiser is not required before phototherapy.NB-UVB is considered ineffective for PPP in clinical practice, and a small RCT did not detect a statistically significant difference between NB-UVB and topical PUVA for clearing PPP. NB-UVB seemed to be similar to selective BB-UVB for clearing CPP.Larger prospective studies are needed to confirm the long-term safety of NB-UVB.
-
Cochrane Db Syst Rev · Oct 2013
Review Meta AnalysisWITHDRAWN: Vitamin C supplementation for asthma.
This Cochrane Review was withdrawn from publication on 23 October 2013 by the Co‐ordinating Editor of the Cochrane Airways Group with the agreement of the authors. The Cochrane Review has been replaced by two new Cochrane Reviews with updated methods: Milan SJ, Hart A, Wilkinson M. Vitamin C for asthma and exercise‐induced bronchoconstriction. ⋯ The uncorrected version of the review (published 21 January 2009) is no longer available in the Cochrane Database of Systematic Reviews, but can be accessed via PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176494/. This statement was revised on 29 October 2018 to clarify the reason for withdrawing the review, provide information about previous amendments to the review, and include a link to the 2009 publication in PubMed Central. The editorial group responsible for this previously published document have withdrawn it from publication.
-
Cochrane Db Syst Rev · Oct 2013
Review Meta AnalysisSingle dose oral celecoxib for acute postoperative pain in adults.
This is an update of a review first published in The Cochrane Library in Issue 4, 2008, and updated in Issue 3, 2012. Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor usually prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis. Celecoxib is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs (NSAIDs). Its effectiveness in acute pain was demonstrated in the earlier reviews. ⋯ Single-dose oral celecoxib is an effective analgesic for postoperative pain relief. Indirect comparison suggests that the 400 mg dose has similar efficacy to ibuprofen 400 mg.
-
Cochrane Db Syst Rev · Oct 2013
ReviewPrimary closure versus delayed closure for non bite traumatic wounds within 24 hours post injury.
Acute traumatic wounds are one of the common reasons why people present to the emergency department. Primary closure has traditionally been reserved for traumatic wounds presenting within six hours of injury and considered 'clean' by the attending surgeon, with the rest undergoing delayed primary closure as a means of controlling wound infection. Primary closure has the potential benefit of rapid wound healing but poses the potential threat of increased wound infection. There is currently no evidence to guide clinical decision-making on the best timing for closure of traumatic wounds. ⋯ There is currently no systematic evidence to guide clinical decision-making regarding the timing for closure of traumatic wounds. There is a need for robust research to investigate the effect of primary closure compared with delayed closure for non bite traumatic wounds presenting within 24 hours of injury.